Market Currents
Salix Pharmaceuticals (SLXP -7.7%) plunges after the FDA provides relatively lenient clinical...
-
Friday, February 10, 2012, 11:02 AM ETSalix Pharmaceuticals (SLXP -7.7%) plunges after the FDA provides relatively lenient clinical study guidelines (.pdf) for would-be makers of a generic version of Salix's Xifaxan drug. Salix closed yesterday near its 52-week high.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
